Although IL-10 has immunosuppressive effects on NK cells, it has pleotropic effects on the regulation of tumor-promoting inflammation, and thus has been tested in clinical trials to augment CD8+ T-cell function against cancer (62). Here, CD8A is linked to neoplasm.